Inhibition of notch signalling and mesangial expansion by combined glucagon like peptide-1 agonist and crocin therapy in animal model of diabetic nephropathy.
Shaimaa Nasr AminEman Mumtaz El-GamalLaila Ahmed RashedAbeer Ibraheem OmarMaged Ahmed HarounPublished in: Archives of physiology and biochemistry (2020)
Diabetic nephropathy (DN) is one of the devastating complications in diabetes mellitus (DM). Glucagon-like peptide-1 (GLP-1) is one of the incretins secreted from L cells in the intestine. Crocin (a carotenoid component of saffron) has antioxidants properties. We investigated the renal effects of Exendin-4 as a GLP-1 agonist and Crocin in DN.Thirty male rats were divided into five groups: control, type II DM, type II DM + Exendin-4, type II DM + Crocin and type II DM + Exendine-4 + Crocin. At the end of the experimental period, systolic and diastolic blood pressures were measured, and GFR was calculated. Blood and urine samples were collected for biochemical analysis. Tissue samples were collected from the kidney for histological examination and biochemical measurements of protein expression.Treatment with GLP-1 agonist or Crocin caused a significant improvement in renal function. Better results were achieved with simultaneous administration of both drugs with inhibition of notch signalling pathway and the related proteins.
Keyphrases
- diabetic nephropathy
- glycemic control
- blood pressure
- left ventricular
- induced apoptosis
- cell proliferation
- heart failure
- type diabetes
- risk factors
- skeletal muscle
- oxidative stress
- metabolic syndrome
- mesenchymal stem cells
- adipose tissue
- endothelial cells
- atrial fibrillation
- high resolution
- single molecule
- combination therapy
- high speed
- pi k akt